No Data
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) issued a profit warning, expecting a net income of 16 million to 20.8 million yuan in 2024, a year-on-year decrease of 81.46% to 85.74%.
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) released its performance forecast for the year 2024, expecting the net profit attributable to shareholders in 2024 to be...
Fujilai: 2024 performance forecast
Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ): A total of 0.9272% of shares have been repurchased.
On January 2, GeLong Hui reported that Fujifilm Holdings Corporation Unsponsored ADR (301258.SZ) announced that as of December 31, 2024, the company had cumulatively repurchased 850,000 shares through a Share Buyback dedicated securities Account via centralized bidding Trade, accounting for 0.9272% of the company's current total share capital, with a highest Fill Price of 28.00 yuan/share, and a lowest Fill Price of 19.63 yuan/share, totaling funds used of 20,139,643.00 yuan (excluding transaction costs).
fujifilm holdings corporation unsponsored adr (301258.SZ): has repurchased 0.6578% of the shares accumulated.
Grain Alliance November 1st | fujifilm holdings corporation unsponsored adr (301258.SZ) announced that as of October 31, 2024, the company has repurchased a total of 603,000 shares of the company through the special securities account for share buyback through centralized competitive bidding trading, accounting for 0.6578% of the company's current total share capital. The highest fill price was 26.42 yuan/share, the lowest fill price was 19.63 yuan/share, and the total amount of funds used was 13.603 million yuan (excluding transaction costs).
fujifilm holdings corporation unsponsored adr (301258.SZ): The active pharmaceutical ingredient Sorafenib Tosylate passed the CDE approval process.
On October 31, Fujilai (301258.SZ) announced that the company's active pharmaceutical ingredient Apatinib Mesylate recently passed the review of the National Medical Products Administration's Drug Evaluation Center (referred to as "CDE"), and the registration number on the CDE platform for active pharmaceutical ingredients, excipients, and packaging materials was changed to "A" status. Apatinib Mesylate is a small molecule tyrosine kinase inhibitor that can inhibit tumor angiogenesis. The approval of the company's Apatinib Mesylate active pharmaceutical ingredient by the CDE indicates that the active pharmaceutical ingredient meets the relevant Chinese drug evaluation technical standards and has been approved for use in domestic market formulations.
Fujilai: Third quarter report 2024
